International AIDS Vaccine Initiative (IAVI)

IAVI’s rVSVdeltaG-LASV-GPC, which is the first Lassa fever vaccine candidate to be evaluated in a Phase II trial, is among the first two products in 2025 to secure a place on PRIME, the European Medic

Now that new mRNA manufacturing technologies have come seemingly out of nowhere to quickly produce billions of COVID-19 vaccine doses, companies are working to optimize them into robust platform techn

Merck & Co., Inc. won’t be the first to deliver an antiviral drug or a vaccine to treat or prevent COVID-19, but the company revealed progress during its third quarter earnings call on an antiviral a

Merck & Co., Inc. prepared investors a few months ago for a disappointing second quarter, so even though total product sales declined 8% year-over-year to $10.87bn in Q2 the company spent much of its